Puma Biotechnology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group reports zero beneficial ownership in Puma Biotechnology Inc. following an internal realignment.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Puma Biotechnology Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Acorn Bioventures Entities and Anders Hove Disclose Significant Passive Stake in Puma Biotechnology, Inc.
Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., their general partners, and manager Anders Hove have filed an amended Schedule 13G, disclosing their collective passive beneficial ownership of 8.0% of Puma Biotechnology, Inc.'s common stock as of December 31, 2024.
NASDAQ
A recent SEC filing reveals that the Frazier Life Sciences investment group has reduced its beneficial ownership in Puma Biotechnology, Inc. to 0.0%, indicating a complete divestment of its previously held stake.
NASDAQ
SCHEDULE 13G/A: Camber Capital Management and Stephen DuBois Divest Entire Stake in Puma Biotechnology
Camber Capital Management LP and Stephen DuBois have filed an amendment to their Schedule 13G, indicating they no longer hold any beneficial ownership in Puma Biotechnology, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Millennium Entities Update Passive Stake in Puma Biotechnology
Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, updating their passive beneficial ownership in Puma Biotechnology, Inc. as of December 31, 2024.